Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Subscribe To Our Newsletter & Stay Updated
